The study listed below is a pharmacokinetic study proposing new, de-escalated dosing strategies for ampicillin for the indication of non-meningitis neonatal sepsis to reduce the risk toxicity associated with high doses of ampicillin in neonates.

Study	Characterization of the Population Pharmacokinetics of Ampicillin in Neonates Using an Opportunistic Study Design
Citation	Tremoulet A, Le J, Poindexter B, et al. Characterization of the population pharmacokinetics of ampicillin in neonates using an opportunistic study design. Antimicrob Agents Chemother. 2014;58(6):3013-3020. doi:10.1128/AAC.02374-13
Objectives	<ul> <li>Characterize the developmental PK of ampicillin prescribed per standard of care to neonates across a wide age spectrum</li> <li>Compare the pharmacodynamic target attainments of various dosing strategies</li> </ul>
Study Design	<ul> <li>Open-label, multicenter, opportunistic, prospective PK study of ampicillin in neonates stratified by gestational age</li> <li>9 centers</li> <li>N = 73 participants, 142 observed drug concentrations</li> </ul>
Methods	<ul> <li>Drug concentrations measured by tandem mass spectrometry</li> <li>OK Data analyzed using population nonlinear mixed-effects modeling</li> <li>Monte Carlo simulations were conducted to determine the probability of target attainment for the time in which the total steady-state ampicillin concentrations remained above the MIC for 50%, 75%, and 100% of the dosing interval</li> <li>N = 73 participants, 142 observed drug concentrations</li> </ul>
Results	<ul> <li>Gestational Age ≤ 34 weeks</li> <li>Postnatal Age 0-7 days - 50 mg/kg/dose, Intravenous, EVERY 12 HOURS</li> <li>Postnatal Age &gt;7 days - 75 mg/kg/dose, Intravenous, EVERY 12 HOURS</li> <li>Gestational Age &gt;34 weeks - 50 mg/kg/dose, Intravenous, EVERY 8 HOURS</li> </ul>
Use for new UW Health order panel	Will be used for de-escalation from meningitis dosing

The following organizations and studies were used in the NeoFax and Lexicomp recommendations and are considered high quality of evidence and strong recommendations per the GRADE criteria:

	Recommendation			Notes		
iopolo KM, Lynfield R, Cummings JJ; American						Used for NeoFax
rademy of Pediatrics, Committee on Fetus and	Amnicillin – Non-meningitis Dosing					recommendation
, and the second	•	PNA		Frequency		
·	≤ 34 weeks	0-7 days				
•		>7 days	75 mg/kg	· ·		
sease. Tealatries. 2013,144(2).020131001	>34 weeks	0-28 days	50 mg/kg	Every 8 Hours		
adley JS, Nelson JD, Barnett ED, et al, eds. Nelson's						Used in Lexicomp and
ediatric Antimicrobial Therapy. 28th ed. American					NeoFax recommendation	
cademy of Pediatrics; 2022:chap 2.	Gentamicin – Neonatal Dosing					
	GA	PI	NA	Dose Fred	uency	
	< 30 weeks	≤	14 days	5 mg/kg Eve	y 48 Hours	
		≥			y 36 Hours	Used in Lexicomp and
' '	30 – 34 weeks				y 36 Hours	NeoFax recommendation
·		13			y 24 Hours	
ediatrics; 2021.	≥ 35 weeks	≤			y 24 Hours	
		8-	60 days	5 mg/kg Eve	y 24 Hours	
m SV Miller II. Amnicillin Dose for Early and Late-	Postnatal Age <	7 days – 100	) ma/ka/dose	Intravenous FVF	SV 8 HOURS	Ampicillin meningitis
,	1 Ostriatar Age 2 7 days 100 mg/ kg/ dose, miliaverious, EVERT 8 1100 MS			dosing as outlined up the		
erinatol. 2022;39(7):717-725. doi:10.1055/s-0040-				6 HOURS	new 2018 Red Book dosing	
18880	J	•	J. J.			
a a communication of the commu	Indemy of Pediatrics, Committee on Fetus and Whorn, Committee on Infectious Diseases.  Inagement of Infants at Risk for Group B Septococcal Sease. Pediatrics. 2019;144(2):e20191881  Idley JS, Nelson JD, Barnett ED, et al, eds. Nelson's Sease. Pediatrics and Inference of Pediatrics; 2022:chap 2.  Indemy of Pediatrics; 2022:chap 2.  Indemy of Pediatrics; 2022:chap 2.  Indeption DW, Barnett ED, Lynfield R, Sawyer MH, and Book: 2021-2024 Report of the Committee on Pectious Diseases. 32nd ed. American Academy of Sections Diseases. 32nd Early and Late-Sect Group B Streptococcal Disease in Neonates. Am Jinatol. 2022;39(7):717-725. doi:10.1055/s-0040-	Ampicillin – N Whorn, Committee on Infectious Diseases. Inagement of Infants at Risk for Group B Peptococcal Pease. Pediatrics. 2019;144(2):e20191881    Sala weeks	Ampicillin – Non-meningit  Ampicillin – Non-meningit  GA PNA  ≤ 34 weeks 0-7 days  > 7 days  > 7 days  > 34 weeks 0-28 days    Sample   Sample   Sample   Sample	Ampicillin – Non-meningitis Dosing  Ampicillin – Non-meningitis Dosing  Bertococcal Bease. Pediatrics. 2019;144(2):e20191881  Ampicillin – Non-meningitis Dosing  GA PNA Dosing  Salveeks 0-7 days 50 mg/kg  Salveeks 0-7 days 50 mg/kg  Salveeks 0-28 days 50 mg/kg  Salveeks 0-3 days 50 mg/kg  Salveeks 0-7 days 50 mg/kg  Salveeks 0-28 days 50 mg/kg  Salveeks 0-28 days 50 mg/kg  Salveeks 0-28 days 50 mg/kg  Salveeks 0-7 days 60 mg/kg  Salveeks 0-7 day	Ampicillin – Non-meningitis Dosing Wborn, Committee on Infectious Diseases. Inagement of Infants at Risk for Group B Exprosoccal Bease. Pediatrics. 2019;144(2):e20191881    Salay   Salay	Ampicillin – Non-meningitis Dosing GA PNA Dosing Frequency ≤ 34 weeks 0-7 days 50 mg/kg Every 12 Hours ≥ 34 weeks 0-8 days 50 mg/kg Every 12 Hours ≥ 34 weeks 0-8 days 50 mg/kg Every 12 Hours ≥ 34 weeks 0-8 days 50 mg/kg Every 12 Hours ≥ 34 weeks 0-8 days 50 mg/kg Every 12 Hours ≥ 34 weeks 0-8 days 50 mg/kg Every 8 Hours    Sometiment of Infants at Risk for Group B Every 24 Hours   Sometiment of Infants at Risk for Group B Every 24 Hours

## **Recommended Dosing Tables**

Ampicillin – Meningitis Dosing				
PNA	Dose	Frequency		
≤ 7 days	100 mg/kg	Every 8 Hours		
>7 days	75 mg/kg	Every 6 Hours		
Ampicillin – Non-menin	gitis Dosing			
GA	PNA	Dosing	Frequency	
≤ 34 weeks	0-7 days	50 mg/kg	Every 12 Hours	
	>7-28 days	75 mg/kg	Every 12 Hours	
>34 weeks	0-28 days	50 mg/kg Every 8 Hours		
Ampicillin – Non-meningitis Dosing				
PNA	Dosing	Frequency		
> 28 days	50 mg/kg	Every 6 Hours		

Gentamicin – Neonatal Dosing				
GA	PNA	Dose	Frequency	
< 30 weeks	≤ 14 days	5 mg/kg	Every 48 Hours	
	≥ 15 days	5 mg/kg	Every 36 Hours	
30 – 34 weeks	≤ 10 days	5 mg/kg	Every 36 Hours	
	11-60 days	5 mg/kg	Every 24 Hours	
≥ 35 weeks	≤ 7 days	4 mg/kg	Every 24 Hours	
	8-60 days	5 mg/kg	Every 24 Hours	

Acyclovir – Neonatal Dosing				
PMA	Dose	Frequency		
<30 weeks	20 mg/kg	Every 12 Hours		
≥30 weeks	20 mg/kg	Every 8 Hours		

Metronidazole – Neonatal Dosing			
Loading Dose: 15 mg/kg ONCE			
PMA	Dose	Frequency	
<34 weeks	7.5 mg/kg	Every 12 Hours	
34-40 weeks	7.5 mg/kg	Every 8 Hours	
>40 weeks	10 mg/kg	Every 8 Hours	


Ceftazidime – Neonatal Dosing				
PNA	Dose	Frequency		
≤7 days	50 mg/kg	Every 12 Hours		
8-28 days	50 mg/kg	Every 8 Hours		

Vancomycin – Neonatal Dosing			
PMA	PNA	Dose	Frequency
≤29 weeks	0-14 days	15 mg/kg	Every 18 Hours
	>14 days	15 mg/kg	Every 12 Hours
30-36 weeks	0-14 days	15 mg/kg	Every 12 Hours
	>14 days	15 mg/kg	Every 8 Hours
37-44 weeks	<7 days	15 mg/kg	Every 12 Hours
	>7 days	15 mg/kg	Every 8 Hours

Cefepime – Neonatal Dosing				
PMA	Dose	Frequency		
<44 weeks	50 mg/kg	Every 12 Hours		

**Gestational Age (GA):** Time elapsed between the first day of the last menstrual period and the day of delivery; reported in weeks **Postnatal Age (PNA):** time elapsed after birth-often considered the chronological age; reported in days, weeks, months **Postmenstrual Age (PMA):** gestational age plus postnatal age; reported in weeks

Antibiotic Selection Algorithm below.



<sup>-</sup>MDR: Multi-drug resistance

<sup>-</sup>HSV: Herpes Simplex Virus

<sup>-</sup>IAI: Intra-abdominal Infection

<sup>-</sup>Risk factors for MDR: previous antibiotic use (specifically broad spectrum/cephalosporin), previous NICU stay, prolonged hospitalization, prolonged antibiotic therapy, presence of a central line or other invasive device, previous infection with MDR organism, neutropenia, underlying renal dysfunction

<sup>-</sup>Narrow antibiotic therapy appropriately when/if culture results available

<sup>-</sup>Broaden to other broad spectrum antibiotic if hx of MDR organism resistant to vanco +/- ceftaz or cefepime (ex: zosyn, meropenem)